A study by the Agency for Healthcare Research and Quality (AHRQ) found that in 2011, sedatives and hypnotics were a leading source for adverse drug events seen in the hospital setting. Approximately % of all ADEs present on admission and % of ADEs that originated during a hospital stay were caused by a sedative or hypnotic drug.  A second study by AHRQ found that in 2011, the most common specifically identified causes of adverse drug events that originated during hospital stays in the . were steroids, antibiotics, opiates/narcotics, and anticoagulants. Patients treated in urban teaching hospitals had higher rates of ADEs involving antibiotics and opiates/narcotics compared to those treated in urban nonteaching hospitals. Those treated in private, nonprofit hospitals had higher rates of most ADE causes compared to patients treated in public or private, for-profit hospitals. 
4. Because of the advantages of alternate-day therapy, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (., patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on alternate-day therapy may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.
mg/m2 PO/IM daily for 4 to 6 weeks or until remission occurs; followed by twice weekly maintenance therapy with a total weekly dose of 30 mg/m2 PO/IM. Children receiving doses of 20 to 30 mg/m2/week ( to 1 mg/kg/week) may have better absorption and fewer GI side effects if methotrexate is administered either IM or subcutaneous. Several different combination chemotherapy regimens have been used for both induction and maintenance therapy in acute lymphoblastic leukemia. The prescriber should be familiar with new advances in antileukemic therapy.